Logo

Merck KGaA's $17B Buy of Sigma-Aldrich Clears US Regulators

Dec 23, 2014 | staff reporter

NEW YORK (GenomeWeb) – Sigma-Aldrich today said that its pending $17 billion acquisition by Merck KGaA has cleared US antitrust hurdles. 

The waiting period under the Hart-Scott-Rodino Antitrust Improvement Act for the proposed deal expired on Monday, clearing the way for the deal in theUS. Sigma-Aldrich and Merck KGaA are awaiting regulatory approval in other countries but continue to expect the deal to be completed in mid-2015.

Sigma-Aldrich shareholders approved the acquisition earlier this month.

Filed under

Regulatory News & FDA Approvals
Drug Discovery & Development
mergers & acquisitions
Merck KGaA
MilliporeSigma
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.